By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Contraceptives > Drospirenone and estetrol > Drospirenone and estetrol Pregnancy and Breastfeeding Warnings
Contraceptives

Drospirenone / estetrol Pregnancy and Breastfeeding Warnings

Contents
Drospirenone and estetrol Pregnancy Warnings Drospirenone and estetrol Breastfeeding Warnings

Drospirenone and estetrol Pregnancy Warnings

Use is not recommended.

AU TGA pregnancy category: B3
US FDA pregnancy category: Not Assigned.

Risk summary:
Epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined oral contraceptives (COC) before conception or during early pregnancy.

Comments:
-Verify pregnancy status prior to administering this drug.
-Discontinue if pregnancy occurs since there is no reason for continued use.
-Placental transfer of estetrol, drospirenone, and/or their metabolites is expected.
-Consider increased risk of venous thromboembolism during the postpartum period when restarting this drug.

Animal studies revealed severe adverse effects on embryofetal development with the individual components of this combination drug. There are no controlled data in human pregnancy.

Embryofetal lethality was reported after oral administration of estetrol to pregnant rats and rabbits at doses yielding systemic exposure levels below or only marginally above the patients. Drospirenone, in combination with ethinylestradiol, also caused embryolethality. Drospirenone administered during the third trimester of pregnancy caused feminization of male fetuses in rats at dose levels that produced systemic exposure 8 to 13 times greater than what was clinically expected.

Last paragraphs:
AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Drospirenone and estetrol Breastfeeding Warnings

Following oral ingestion of drospirenone 3 mg/ethinyl estradiol 30 mcg, about 0.02% of the drospirenone dose was measured in breast milk within 24 hours. Based on these results, the potential maximal dose a breastfed infant would receive is estimated to be less than 1 mcg/day. COCs might affect infant growth negatively during the first month of use. The magnitude of the effect is likely dependent on dose and the time COC was introduced postpartum. In the US, expert opinion advises women not to use COCs during the first 3 weeks after delivery because of concerns about increased risk for venous thromboembolism and to not use COCs during the fourth week postpartum because of potential effects on breastfeeding performance.

Women with other risk factors for venous thromboembolism should not use COCs for 4 to 6 weeks after delivery. WHO guidelines advise against the use of COCs for 6 months postpartum if breastfeeding.

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Yes

Comments:
-Inform postpartum females that this medication can decrease milk production.
-When possible, other methods of contraception should be used while breast-feeding.
-The WHO also advises against the use of COC in breastfeeding women 6 weeks to 6 months postpartum, as the risk of COCs does not outweigh the benefit.

See references

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by